ACCORD 2

A multicentre, seamless, Phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients.

Type: Interventional

Site and lead:

  • Oxford Road Campus: Dr Maya Buch
  • Wythenshawe Hospital: Dr Alexander Horsley

Patient group: All COVID-19 patients

Intervention:

  • Bemcentinib

Funder: Not available

Sponsor: University Hospital Southampton NHS Foundation Trust

  • ACCORD 2 is a nationally-prioritised COVID-19 study. See the full list Urgent Public Health COVID-19 Studies on the NIHR website.

More about ACCORD-2

This adaptive platform study is designed to rapidly assess multiple candidate agents as treatments for COVID 19. The plan is to add candidate agents as they are identified, and to remove therapies once they have completed their evaluation.